Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Sang S., Datoo MS., Otieno E., Muiruri C., Bellamy D., Gathuri E., Ngoto O., Musembi J., Provstgaard-Morys S., Stockdale L., Aboagye J., Woods D., Lawrie A., Roberts R., Keter K., Kimani D., Ndungu F., Kapulu M., Njau I., Orindi B., Ewer KJ., Hill AVS., Bejon P., Hamaluba M.